COMMUNIQUÉS West-GlobeNewswire
-
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
01/07/2026 -
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
01/07/2026 -
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT
01/07/2026 -
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma
01/07/2026 -
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
01/07/2026 -
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
01/07/2026 -
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
01/07/2026 -
Human Appeal supports Syrian farmers through new wheat supply chain project
01/07/2026 -
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
01/07/2026 -
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026 -
Stryker to announce second quarter 2026 financial results
01/07/2026 -
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
01/07/2026 -
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
01/07/2026 -
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
01/07/2026 -
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
01/07/2026 -
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
01/07/2026 -
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
01/07/2026 -
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
01/07/2026 -
Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology
01/07/2026
Pages